T3-Max-100 Liothyronine


SKU: 520 Category:

Manufacturer: Maxtreme
Substance: Liothyronine
Package: 100 mcg / tab. (50 tab.)


T3-Max-100 is a chemically synthesized thyroid hormone modification produced by Maxtreme Pharma. The active ingredient of the drug is Liothyronine Sodium (T3). Initially, T3 was developed for medical purposes in the treatment of hypothyroidism, which is a disease directly related to the malfunction of the thyroid gland. T3 has also been prescribed for patients with acute iodine deficiency. If left untreated, lipothyroidism leads to complications such as malfunction of the pituitary gland. In addition, the active components of T3 have a positive effect on metabolic processes, improve the functioning of the heart muscle and stimulate the synthesis of growth hormone.

Advantages of T3

Today, the drug is used not only for medical, but also for sports purposes, this is because the drug is able to stimulate the processes of protein synthesis. Furthermore, T3 helps to accelerate metabolic processes, thus stimulating the processes of breaking down fat cells. Therefore, with the help of this drug, you can:

  • Stimulate metabolic processes
  • Increase the resistance
  • Stimulate the reduction of fat cells
  • Increase the effectiveness of your training

To get the above results from the cycle and to avoid possible side effects, the user must take T3 with the prescription of a specialist.

Rules for taking the drug

Regardless of your experience with taking this drug, the T3 cycle should be started with a minimum daily dosage, which is usually around 25mcg (1/4 tablet). Thereafter, the dose should be increased up to 100mcg. The cycle length can be up to 6 weeks. The athlete must keep their body weight under control throughout the period of the cycle.

Further positive results from the T3 cycle can be achieved by combining the drug with clenbuterol, testosterone propionate and oxandrolone.


There are no reviews yet.

Be the first to review “T3-Max-100 Liothyronine”

Your email address will not be published. Required fields are marked *